ALBANY, N.Y. (AP) — Multinational drugmaker GlaxoSmithKline is paying New York, 43 other states and the District of Columbia $105 million to settle complaints that the company unlawfully marketed three drugs.
New York Attorney General Eric Schneiderman says the state’s share of the settlement is more than $4.1 million. The settlement resolves allegations that the London-based company illegally marketed Advair, Paxil and Wellbutrin for purposes that hadn’t been approved by the U.S. Food and Drug Administration.
GSK is prohibited from disseminating information that describes any so-called off-label use.
The asthma drug Advair is Glaxo’s best-selling product. Paxil and Wellbutrin are antidepressants.
The company signed the consent agreement last week. It said it admitted no wrongdoing and resolved legal claims from old issues with state trade practice laws similar to its settlement in 2012 with the federal government.